|Other Names||Kallikrein-11, hK11, 3421-, Hippostasin, Serine protease 20, Trypsin-like protease, Kallikrein-11 inactive chain 1, Kallikrein-11 inactive chain 2, KLK11, PRSS20, TLSP|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP6330b was selected from the Center region of human KLK11. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Possible multifunctional protease. Efficiently cleaves 'bz-Phe-Arg-4-methylcoumaryl-7-amide', a kallikrein substrate, and weakly cleaves other substrates for kallikrein and trypsin. Cleaves synthetic peptides after arginine but not lysine residues.|
|Cellular Location||Isoform 1: Secreted.|
|Tissue Location||Expressed in brain, skin and prostate. Isoform 1 is expressed preferentially in brain. Isoform 2 is expressed in prostate. Present in seminal plasma at concentrations ranging from 2 to 37 microg/mL (at protein level)|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. KLK11, also known as hippostatin, is a kallikrein-like serine protease, which has two alternatively spliced isoforms, brain-type and prostate-type. KLK11 plays a role in the prostate, including reproductive and/or tumorigenic functions. Elevated serum levels of KLLK11 are found in 70% of women with ovarian cancer and in 60% of men with prostate cancer. Analysis of the KLK11 biomarker in serum may aid in the diagnosis and monitoring of ovarian and prostatic carcinoma.
Diamandis, E.P., et al., Clin. Biochem. 37(9):823-829 (2004).Shigemasa, K., et al., Clin. Cancer Res. 10(8):2766-2770 (2004).Borgono, C.A., et al., Int. J. Cancer 106(4):605-610 (2003).Clark, H.F., et al., Genome Res. 13(10):2265-2270 (2003).Nakamura, T., et al., Urology 61(5):1042-1046 (2003).
If you have any additional inquiries please email technical services at email@example.com.